Form 4: Ovid Therapeutics Director Barbara Duncan Granted Stock Options

Ovid Therapeutics director Barbara Duncan was granted 90,000 stock options, vesting monthly over three years.

Summary

• Ovid Therapeutics director Barbara Duncan was granted 90,000 stock options on December 12, 2024.
• The options have an exercise price of $1.06 per share.
• The options will vest in 36 equal monthly installments, contingent on Ms. Duncan's continued service.
• The options expire on December 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating directors in the biotechnology industry.
• The vesting schedule of 36 months is typical for such grants, encouraging long-term commitment.
• The exercise price is set at a specific value, which is common practice.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, director, Ovid Therapeutics, insider trading, equity compensation, vesting